Injection drug use practices and HIV infection among people who inject drugs in Kigali, Rwanda: a cross-sectional study.
HIV
Injection drug use
Kigali
People who inject drugs
Rwanda
Journal
Harm reduction journal
ISSN: 1477-7517
Titre abrégé: Harm Reduct J
Pays: England
ID NLM: 101153624
Informations de publication
Date de publication:
15 12 2021
15 12 2021
Historique:
received:
28
09
2021
accepted:
30
11
2021
entrez:
16
12
2021
pubmed:
17
12
2021
medline:
27
1
2022
Statut:
epublish
Résumé
In Rwanda, epidemiological data characterizing people who inject drugs (PWID) and their burden of HIV are limited. We examined injection drug use (IDU) history and practices, and HIV infection in a sample of PWID in Kigali. From October 2019 to February 2020, 307 PWID aged ≥ 18 were enrolled in a cross-sectional study using convenience sampling in Kigali. Participants completed interviewer-administered questionnaires on IDU history and practices and HIV testing. We used Poisson regression with robust variance estimation to assess IDU practices associated with HIV infection and assessed factors associated with needle sharing in the six months preceding the study. The median age was 28 years (IQR 24-31); 81% (251) were males. Female PWID were more likely to report recent IDU initiation, selling sex for drugs, and to have been injected by a sex partner (p < 0.05). In the prior six months, heroin was the primary drug of choice for 99% (303) of participants, with cocaine and methamphetamine also reported by 10% (31/307) and 4% (12/307), respectively. In total, 91% (280/307) of participants reported ever sharing needles in their lifetime and 43% (133) knew someone who died from a drug-related overdose. HIV prevalence was 9.5% (95% CI 8.7-9.3). Sharing needles at least half of the time in the previous six months was positively associated with HIV infection (adjusted prevalence ratio (aPR) 2.67; 95% CI 1.23-5.78). Overall, 31% (94/307) shared needles and 33% (103/307) reused needles in the prior six months. Female PWID were more likely to share needles compared to males (aPR 1.68; 95% CI 1.09-2.59). Additionally, bisexual PWID (aPR 1.68; 95% CI 1.09-2.59), those who shared needles at the first injection (aPR 2.18; 95% CI 1.59-2.99), reused needles recently (aPR 2.27; 95% CI 1.51-3.43) and shared other drug paraphernalia (aPR 3.56; 95% CI 2.19-5.81) were more likely to report recent needle sharing. HIV infection was common in this study. The high prevalence of needle reuse and sharing practices highlights significant risks for onward transmission and acquisition of HIV and viral hepatitis. These data highlight the urgent need for PWID-focused harm reduction services in Rwanda, including syringe services programs, safe injection education, naloxone distribution, and substance use disorder treatment programs and optimizing these services to the varied needs of people who use drugs in Rwanda.
Sections du résumé
BACKGROUND
In Rwanda, epidemiological data characterizing people who inject drugs (PWID) and their burden of HIV are limited. We examined injection drug use (IDU) history and practices, and HIV infection in a sample of PWID in Kigali.
METHODS
From October 2019 to February 2020, 307 PWID aged ≥ 18 were enrolled in a cross-sectional study using convenience sampling in Kigali. Participants completed interviewer-administered questionnaires on IDU history and practices and HIV testing. We used Poisson regression with robust variance estimation to assess IDU practices associated with HIV infection and assessed factors associated with needle sharing in the six months preceding the study.
RESULTS
The median age was 28 years (IQR 24-31); 81% (251) were males. Female PWID were more likely to report recent IDU initiation, selling sex for drugs, and to have been injected by a sex partner (p < 0.05). In the prior six months, heroin was the primary drug of choice for 99% (303) of participants, with cocaine and methamphetamine also reported by 10% (31/307) and 4% (12/307), respectively. In total, 91% (280/307) of participants reported ever sharing needles in their lifetime and 43% (133) knew someone who died from a drug-related overdose. HIV prevalence was 9.5% (95% CI 8.7-9.3). Sharing needles at least half of the time in the previous six months was positively associated with HIV infection (adjusted prevalence ratio (aPR) 2.67; 95% CI 1.23-5.78). Overall, 31% (94/307) shared needles and 33% (103/307) reused needles in the prior six months. Female PWID were more likely to share needles compared to males (aPR 1.68; 95% CI 1.09-2.59). Additionally, bisexual PWID (aPR 1.68; 95% CI 1.09-2.59), those who shared needles at the first injection (aPR 2.18; 95% CI 1.59-2.99), reused needles recently (aPR 2.27; 95% CI 1.51-3.43) and shared other drug paraphernalia (aPR 3.56; 95% CI 2.19-5.81) were more likely to report recent needle sharing.
CONCLUSION
HIV infection was common in this study. The high prevalence of needle reuse and sharing practices highlights significant risks for onward transmission and acquisition of HIV and viral hepatitis. These data highlight the urgent need for PWID-focused harm reduction services in Rwanda, including syringe services programs, safe injection education, naloxone distribution, and substance use disorder treatment programs and optimizing these services to the varied needs of people who use drugs in Rwanda.
Identifiants
pubmed: 34911554
doi: 10.1186/s12954-021-00579-0
pii: 10.1186/s12954-021-00579-0
pmc: PMC8672501
doi:
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
130Subventions
Organisme : NIMH NIH HHS
ID : R01 MH110358
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI102623
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s).
Références
Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192–207.
doi: 10.1016/S2214-109X(17)30375-3
World Drug Report 2020. 2021.
Grebely J, Larney S, Peacock A, Colledge S, Leung J, Hickman M, et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction. 2019;114(1):150–66.
doi: 10.1111/add.14393
Jürgens R, Csete J, Amon JJ, Baral S, Beyrer C. People who use drugs, HIV, and human rights. The Lancet. 2010;376(9739):475–85.
doi: 10.1016/S0140-6736(10)60830-6
WHO. ATLAS on substance use 2017: resources for the prevention and treatment of substance use disorders. Geneva: World Health Organization; 2017.
Malta M, Ralil da Costa M, Bastos FI. The paradigm of universal access to HIV-treatment and human rights violation: how do we treat HIV-positive people who use drugs? Curr HIV/AIDS Rep. 2014;11(1):52–62.
doi: 10.1007/s11904-013-0196-2
Campeau L, Blouin K, Leclerc P, Alary M, Morissette C, Blanchette C, et al. Impact of sex work on risk behaviours and their association with HIV positivity among people who inject drugs in Eastern Central Canada: cross-sectional results from an open cohort study. BMJ Open. 2018;8(1):e019388.
doi: 10.1136/bmjopen-2017-019388
Larney S, Peacock A, Leung J, Colledge S, Hickman M, Vickerman P, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health. 2017;5(12):e1208–20.
doi: 10.1016/S2214-109X(17)30373-X
Dewing S, Plüddemann A, Myers BJ, Parry CDH. Review of injection drug use in six African countries: Egypt, Kenya, Mauritius, Nigeria, South Africa and Tanzania. 2009. https://doi.org/10.1080/09687630500480228
UNAIDS. 2020 Global AIDS update—seizing the moment—tackling entrenched inequalities to end epidemics. UNAIDS; 2020.
Twahirwa Rwema JO, Lyons CE, Herbst S, Liestman B, Nyombayire J, Ketende S, et al. HIV infection and engagement in HIV care cascade among men who have sex with men and transgender women in Kigali, Rwanda: a cross-sectional study. J Int AIDS Soc. 2020;23(S6):e25604.
doi: 10.1002/jia2.25604
Twahirwa Rwema JO, Herbst S, Hamill MM, Liestman B, Nyombayire J, Lyons CE, et al. Cross-sectional assessment of determinants of STIs among men who have sex with men and transgender women in Kigali, Rwanda. Sex Transm Infect. 2021:sextrans-2020–054753.
Ingabire R, Parker R, Nyombayire J, Ko JE, Mukamuyango J, Bizimana J, et al. Female sex workers in Kigali, Rwanda: a key population at risk of HIV, sexually transmitted infections, and unplanned pregnancy. Int J STD AIDS. 2019;30(6):557–68.
doi: 10.1177/0956462418817050
Health Mo. National Guidelines for Prevention and Management of HIV. Kigali, Rwanda: Ministry of Health—Rwanda Biomedical Center, HIV & AIDS SaOD; 2018 2016.
NISR. Rwanda Demographic and Health Survey 2014–15—Final Report. Kigali - Rwanda: National Insitute of Statistics of Rwanda 2016.
Baltazar CS, Horth R, Boothe M, Sathane I, Young P, Langa DC, et al. High prevalence of HIV, HBsAg and anti-HCV positivity among people who injected drugs: results of the first bio-behavioral survey using respondent-driven sampling in two urban areas in Mozambique. BMC Infect Dis. 2019;19(1):1–13.
doi: 10.1186/s12879-018-3567-x
Kurth AE, Cleland CM, DesJarlais DC, Musyoki H, Lizcano JA, Chhun N, et al. HIV prevalence, estimated incidence, and risk behaviors among people who inject drugs in Kenya. J Acquir Immune Defic Syndr. 2015;70(4):420.
doi: 10.1097/QAI.0000000000000769
Tun W, Sheehy M, Broz D, Okal J, Muraguri N, Raymond HF, et al. HIV and STI prevalence and injection behaviors among people who inject drugs in Nairobi: results from a 2011 bio-behavioral study using respondent-driven sampling. AIDS Behav. 2015;19(1):24–35.
doi: 10.1007/s10461-014-0936-3
Scheibe A, Young K, Moses L, Basson RL, Versfeld A, Spearman CW, et al. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey. Harm Reduct J. 2019;16(1):1–11.
doi: 10.1186/s12954-019-0298-2
Brookmeyer KA, Haderxhanaj LT, Hogben M, Leichliter J. Sexual risk behaviors and STDs among persons who inject drugs: a national study. Prev Med. 2019;126:105779.
doi: 10.1016/j.ypmed.2019.105779
Wurcel AG, Anderson JE, Chui KK, Skinner S, Knox TA, Snydman DR, et al editors. Increasing infectious endocarditis admissions among young people who inject drugs. Open forum infectious diseases. Oxford: Oxford University Press; 2016.
Tan C, Shojaei E, Wiener J, Shah M, Koivu S, Silverman M. Risk of new bloodstream infections and mortality among people who inject drugs with infective endocarditis. JAMA Netw Open. 2020;3(8):e2012974.
doi: 10.1001/jamanetworkopen.2020.12974
Wright T, Hope V, Ciccarone D, Lewer D, Scott J, Harris M. Prevalence and severity of abscesses and cellulitis, and their associations with other health outcomes, in a community-based study of people who inject drugs in London, UK. PLoS ONE. 2020;15(7):e0235350.
doi: 10.1371/journal.pone.0235350
Drugs UNOo, Crime INoPWUD, Joint United Nations Programme on HIV/AIDS. Implementing comprehensive HIV and HCV programmes with people who inject drugs: practical guidance for collaborative interventions. United Nations Office on Drugs and Crime Vienna; 2017.
Strathdee SA, Celentano DD, Shah N, Lyles C, Stambolis VA, Macalino G, et al. Needle-exchange attendance and health care utilization promote entry into detoxification. J Urban Health. 1999;76(4):448–60.
doi: 10.1007/BF02351502
Hagan H, McGough JP, Thiede H, Hopkins S, Duchin J, Alexander ER. Reduced injection frequency and increased entry and retention in drug treatment associated with needle-exchange participation in Seattle drug injectors. J Subst Abuse Treat. 2000;19(3):247–52.
doi: 10.1016/S0740-5472(00)00104-5
Riley ED, Kral AH, Stopka TJ, Garfein RS, Reuckhaus P, Bluthenthal RN. Access to sterile syringes through San Francisco pharmacies and the association with HIV risk behavior among injection drug users. J Urban Health. 2010;87(4):534–42.
doi: 10.1007/s11524-010-9468-y
Health RMo. National list of essential medicines for adults 6th edition. Kigali, Rwanda2015.
Bennett AS, Bell A, Tomedi L, Hulsey EG, Kral AH. Characteristics of an overdose prevention, response, and naloxone distribution program in Pittsburgh and Allegheny County, Pennsylvania. J Urban Health. 2011;88(6):1020–30.
doi: 10.1007/s11524-011-9600-7
Leece PN, Hopkins S, Marshall C, Orkin A, Gassanov MA, Shahin RM. Development and implementation of an opioid overdose prevention and response program in Toronto, Ontario. Can J Public Health. 2013;104(3):e200–4.
doi: 10.17269/cjph.104.3788
Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med. 2014;8(3):153–63.
doi: 10.1097/ADM.0000000000000034
DRUGS UNOO, LABOR. WORLD DRUG REPORT 2020 (SET OF 6 BOOKLETS): UN; 2021.
Atkinson J, McCurdy S, Williams M, Mbwambo J, Kilonzo G. HIV risk behaviours, perceived severity of drug use problems, and prior treatment experience in a sample of young heroin injectors in Dar es Salaam, Tanzania. Afr J Drug Alcohol Stud. 2011;10(1):1–9.
pubmed: 23024611
pmcid: 3460543
Jain JP, Abramovitz D, Strathdee SA, Gonzalez-Zuniga P, Rangel G, West BS, et al. Sex work as a mediator between female gender and incident HIV infection among people who inject drugs in Tijuana, Mexico. AIDS Behav. 2020;24(9):2720–31.
doi: 10.1007/s10461-020-02828-y
Des Jarlais DC, McKnight C, Feelemyer J, Arasteh K, Tross S, Campbell AN, et al. Heterosexual male and female disparities in HIV infection at the end of an epidemic: HIV infection among persons who inject drugs in New York City, 2001–2005 and 2011–2015. Drug Alcohol Depend. 2018;185:391–7.
doi: 10.1016/j.drugalcdep.2017.12.039
Ghosh D, Krishnan A, Gibson B, Brown SE, Latkin CA, Altice FL. Social network strategies to address HIV prevention and treatment continuum of care among at-risk and HIV-infected substance users: a systematic scoping review. AIDS Behav. 2017;21(4):1183–207.
doi: 10.1007/s10461-016-1413-y
Heckathorn DD. Respondent-driven sampling II: deriving valid population estimates from chain-referral samples of hidden populations. Soc Probl. 2002;49(1):11–34.
doi: 10.1525/sp.2002.49.1.11
Heckathorn DD, Wangroongsarb P, Thwing J, Eliades J, Satimai W, Delacollette C, et al. Respondent-driven sampling: a new approach to the study of hidden populations. Soc Probl. 1997;44(2):174–99.
doi: 10.2307/3096941